Stirling Products (ASX: STI) has been granted a trading halt by the ASX, pending several major announcements, with the company's shares placed in pre-open.
Stirling will update the market on:
1. Company strategic review advice;
2. TeleMedCare and Stirling Pharma progress and developments;
3. First exclusive HDA platform licensing for the pulmonary delivery of a major drug; and
4. Proposed UK AIM listing and funding.
The trading halt will last to the earlier of the announcement(s), or trading on Wednesday 15 June.